22,966 Cases: The Poison Center Record on GLP-1 Exposures, 2019–2025
A 1,500% increase in call volume, mostly accidental therapeutic errors, and one failure mode specific to compounded products. What this dataset supports and what it does not.
Findings
- America's Poison Centers reports managing 22,966 GLP-1 agonist exposure cases from 2019 through 2025.
- Call volume increased nearly 1,500% across that period.
- Most cases involved accidental therapeutic errors with FDA-approved drugs.
- Compounded products have been specifically associated with 10-fold dosing mistakes caused by confusion over syringe measurement units.
Poison center data is a different instrument from adverse event reporting, and in some respects a better one. Calls are logged in real time by trained specialists during an active incident, and the record captures what happened rather than what someone later chose to report.
The dataset
What a 1,500% increase does and does not mean
The obvious confounder is prescription volume. GLP-1 use expanded enormously across this period. A large rise in calls partly reflects a large rise in the number of people taking these drugs, and the poison center dataset does not carry a denominator that would let you compute a per-patient rate.
What the data does support is the shape of the problem. Most cases were accidental therapeutic errors — people taking the wrong amount by mistake, not overdosing intentionally and not experiencing an idiosyncratic reaction. That is an instruction, labelling, and device-design finding.
Compounded products have been associated with 10-fold dosing mistakes caused by confusion over syringe measurement units. That is not a pharmacology finding. It is a finding about how the product is packaged and how the dose is communicated, and it is entirely preventable by design.
The mechanism of the 10x error
A prescription is written in milligrams. A compounded multidose vial is dispensed with insulin syringes marked in units. Converting between the two requires knowing the concentration of that specific vial, which varies between pharmacies and between batches.
The conversions commonly involve a factor of ten. A single misplaced decimal — or reading a syringe graduation as a whole unit when it represents a tenth — produces a clean ten-fold error rather than a small one. Because these drugs have long half-lives, the consequence persists for days rather than hours.
Brand-name products dispensed in prefilled pens do not have this failure mode. The device performs the measurement.
How this dataset relates to the FDA reporting file
The two should be read together, not interchangeably. As of May 31, 2026, the FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The agency cautions that those reports do not establish causation, and that the totals are likely undercounts because many state-licensed pharmacies are not required to report adverse events.
The poison center file captures acute incidents in real time. The FDA file captures what gets voluntarily reported afterward, in a market where a large share of dispensers face no reporting obligation at all. Both point at the same error class.
- The per-patient exposure rate, in the absence of a reliable denominator.
- What proportion of the 22,966 cases involved compounded rather than approved product.
- Clinical outcomes and hospitalisation rates across the case series.
- Whether the error rate differs measurably between multidose vial and prefilled presentations, which would require a controlled comparison nobody has published.
The design conclusion
The most defensible reading of this dataset is not that GLP-1s are dangerous. It is that a specific, repeated, preventable error is being generated by a dispensing format chosen for cost reasons, and that the cost of the resulting errors is borne by patients rather than by the entities that chose the format.
That is a solvable problem. It is solved by prefilled or single-dose presentations, by dosing instructions written in the units printed on the syringe the patient actually received, and by concentration labelling that does not require arithmetic at the kitchen table.
Primary sources & citations
- America's Poison Centers, GLP-1 agonist exposure case data, 2019 through 2025.
- Drug Discovery Trends, reporting on poison center case totals and compounded GLP-1 dosing errors.
- US Food and Drug Administration adverse event report totals for compounded semaglutide and tirzepatide as of May 31, 2026.
- FDA statements on the limitations of passive adverse event surveillance and on underreporting by state-licensed pharmacies.
Editorial note
Looking for a provider rather than a citation?
This site does not review or rank telehealth providers inside its research articles, and carries no provider links in article text. Our provider comparison grid, including how each one is monetized, lives on the homepage.
Open the provider grid